WA
STML

WealthTrust-Arizona’s Stemline Therapeutics, Inc. STML Stock Holding History

WealthTrust-Arizona’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$1K – 668
2014
Q2 		$1K Buy
+100
New +$1.53K ﹤0.01% 617

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

WealthTrust-Arizona's STML Position: Q3 2014 in Review

WealthTrust-Arizona sold out of Stemline Therapeutics, Inc. (STML) in Q3 2014, closing a stake of 100 shares — an estimated $1K sold.

WealthTrust-Arizona first reported a position in STML in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 61 funds tracked by Wall St. Rank hold STML as of Q3 2014.

  • WealthTrust-Arizona reported no remaining Stemline Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • WealthTrust-Arizona sold 100 Stemline Therapeutics, Inc. shares in Q3 2014, an estimated $1K.
  • WealthTrust-Arizona first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • WealthTrust-Arizona's Stemline Therapeutics, Inc. position peaked at $1K in Q2 2014.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2014.

Based on WealthTrust-Arizona's 13F filing for Q3 2014, filed 23 Oct 2014.